Withdrawal Symptoms Following Discontinuation of Vortioxetine-Retrospective Chart Review
- PMID: 34064611
- PMCID: PMC8151377
- DOI: 10.3390/ph14050451
Withdrawal Symptoms Following Discontinuation of Vortioxetine-Retrospective Chart Review
Abstract
The efficacy of vortioxetine has been proven in many studies, but data concerning discontinuation symptoms (DS) after vortioxetine withdrawal is scarce. The aim of our study is to systematically evaluate the prevalence, determinants, and clinical features of vortioxetine DS in a retrospective chart review. Data were obtained from medical records of 263 adult patients with depressive disorders who discontinued former vortioxetine treatment. DS were observed in eight (3%) patients after 71-375 days (median 272) of treatment. DS emerged after median three days following vortioxetine withdrawal and lasted for median seven days. The clinical presentation of DS involved: emotional lability (100% of patients), irritability (75%), sudden worsening of mood (75%), nervousness (37.5%), and agitation (37.5%). Median DESS score was four (range of four to six). DS were significantly more prevalent after accidental vs. planned discontinuation (adjusted p = 0.011) and were less frequent after switching to a different antidepressant vs. ceasing pharmacotherapy (adjusted p = 0.0165). DS appeared more often if patients discontinued therapy without medical consultation (adjusted p = 0.033). The occurrence of DS was not associated with the dose and way of drug discontinuation (sudden vs. gradual). In sum, our results show that clinicians should be aware that vortioxetine withdrawal is associated with the possibility of DS.
Keywords: antidepressants; discontinuation symptoms; retrospective chart review; vortioxetine; withdrawal.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Case Report: Vortioxetine in the Treatment of Depressive Symptoms in Patients With Epilepsy-Case Series.Front Pharmacol. 2022 Mar 31;13:852042. doi: 10.3389/fphar.2022.852042. eCollection 2022. Front Pharmacol. 2022. PMID: 35431973 Free PMC article.
-
Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial.J Sex Med. 2019 Oct;16(10):1638-1649. doi: 10.1016/j.jsxm.2019.06.018. Epub 2019 Aug 9. J Sex Med. 2019. PMID: 31405765 Clinical Trial.
-
Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats.Behav Brain Res. 2013 Nov 1;256:520-8. doi: 10.1016/j.bbr.2013.09.002. Epub 2013 Sep 7. Behav Brain Res. 2013. PMID: 24016840
-
Vortioxetine: A new alternative for the treatment of major depressive disorder.Rev Psiquiatr Salud Ment (Engl Ed). 2018 Jan-Mar;11(1):48-59. doi: 10.1016/j.rpsm.2017.06.006. Epub 2017 Aug 8. Rev Psiquiatr Salud Ment (Engl Ed). 2018. PMID: 28800937 Review. English, Spanish.
-
Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature.Ther Clin Risk Manag. 2015 Aug 12;11:1193-212. doi: 10.2147/TCRM.S55313. eCollection 2015. Ther Clin Risk Manag. 2015. PMID: 26316764 Free PMC article. Review.
Cited by
-
SSRIs in the Treatment of Depression: A Pharmacological CUL-DE-SAC?Curr Top Behav Neurosci. 2024;66:1-19. doi: 10.1007/7854_2023_447. Curr Top Behav Neurosci. 2024. PMID: 37922101 Review.
-
Case Report: Vortioxetine in the Treatment of Depressive Symptoms in Patients With Epilepsy-Case Series.Front Pharmacol. 2022 Mar 31;13:852042. doi: 10.3389/fphar.2022.852042. eCollection 2022. Front Pharmacol. 2022. PMID: 35431973 Free PMC article.
-
Effectiveness and Tolerability of Vortioxetine Oral Drops Versus Oral Tablets in Major Depressive Disorder: An Analysis of a Real-World Cohort Study in Switzerland.CNS Drugs. 2025 Jul 27. doi: 10.1007/s40263-025-01207-2. Online ahead of print. CNS Drugs. 2025. PMID: 40717157
-
Incidence and risk factors of antidepressant withdrawal symptoms: a meta-analysis and systematic review.Mol Psychiatry. 2025 May;30(5):1758-1769. doi: 10.1038/s41380-024-02782-4. Epub 2024 Oct 11. Mol Psychiatry. 2025. PMID: 39394455
-
Deprescribing Antidepressants in Children and Adolescents: A Systematic Review of Discontinuation Approaches, Cross-Titration, and Withdrawal Symptoms.J Child Adolesc Psychopharmacol. 2025 Feb;35(1):3-22. doi: 10.1089/cap.2024.0099. Epub 2024 Oct 29. J Child Adolesc Psychopharmacol. 2025. PMID: 39469761
References
-
- Grohol J. Top 25 Psychiatric Medication Prescriptions for 2013. [(accessed on 18 April 2021)]; Available online: https://psychcentral.com/lib/top-25-psychiatric-medication-prescriptions...
-
- Heitzman J., Solak M. Zespół objawów odstawiennych po lekach antydepresyjnych w badaniach naukowych-Implikacje dla lekarzy i pacjentów. Psychiatr. Pol. 2009;43:545–555. - PubMed
-
- Warner C.H., Bobo W., Warner C., Reid S., Rachal J. Antidepressant discontinuation syndrome. Am. Fam. Physician. 2006;74:449–456. - PubMed
LinkOut - more resources
Full Text Sources